Evotec SE Announces Confidential Submission of Draft Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a Proposed Offering of American Depositary Shares

Rhea-AI Summary

Evotec SE has confidentially submitted a Registration Statement on Form F-1 to the U.S. SEC for a proposed offering of shares represented by American Depositary Shares (ADSs). The final number of ADSs and their pricing are yet to be determined. This move is intended to secure a secondary listing on the Nasdaq Global Select Market under the ticker symbol EVO. The anticipated trading start is in the second half of 2021, pending SEC approval.

Positive

• Confidential submission of Registration Statement for offering of ADSs.
• Seeking secondary listing on Nasdaq under ticker symbol EVO.

Negative

• Final number of ADSs and pricing are not yet determined.
• Timing of the first trading day remains subject to change.

HAMBURG, GERMANY / ACCESSWIRE / August 2, 2021 / Evotec SE (Frankfurt Stock Exchange; EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) announces that it confidentially submitted a Registration Statement on Form F-1 ("Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") for a proposed offering and sale in the United States of shares of Evotec represented by American Depositary Shares ("ADSs"). The Registration Statement has not yet become effective and the final number of ADSs to be offered and their price have not yet been determined.

Evotec's shares are listed on the regulated market of the Frankfurt Stock Exchange in Germany with additional admission obligations of the Prime Standard Segment. Evotec will seek a secondary listing of the ADSs on the Nasdaq Global Select Market in the United States under the ticker symbol "EVO". The new shares underlying the ADSs will be issued from Evotec's authorized capital. The first day of trading of the ADSs is expected to occur during the second half of 2021, however, this timing remains subject to change.

The ADSs referred to in this announcement are to be offered only by means of a registration statement on Form F-1 approved by the SEC. In accordance with applicable capital markets requirements, Evotec will announce when the registration statement has been approved by the SEC, including further details, such as final number and price of ADS.

- End of the ad hoc release -

This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations, or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the U.S. Securities Act of 1933, as amended ("Securities Act"), and other applicable securities laws. This announcement is being issued in accordance with Rule 135 under the Securities Act and other applicable securities laws. This public disclosure of inside information does not constitute a prospectus.

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:

Dr Werner Lanthaler, Chief Executive Officer

Evotec SE
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg, Germany

Phone: +49.(0)40.560 81-242
Email: werner.lanthaler@evotec.com

SOURCE: Evotec AG

View source version on accesswire.com:
https://www.accesswire.com/657956/Evotec-SE-Announces-Confidential-Submission-of-Draft-Registration-Statement-on-Form-F-1-with-the-US-Securities-and-Exchange-Commission-for-a-Proposed-Offering-of-American-Depositary-Shares

FAQ

What is Evotec SE planning with the Registration Statement on Form F-1?

Evotec SE is planning to offer shares represented by American Depositary Shares (ADSs) through a confidential submission to the U.S. SEC.

When is Evotec's ADSs expected to start trading?

The ADSs are expected to begin trading in the second half of 2021, but the timing is subject to change.

What ticker symbol will Evotec use for its ADSs on Nasdaq?

Evotec will use the ticker symbol EVO for its ADSs on Nasdaq.

What details are still pending regarding Evotec's proposed offering?

The final number of ADSs to be offered and their price have not yet been determined.